PDS Documentation Hub
The data contained in Enroll-HD PDS5 was extracted from the Enroll-HD electronic data capture (EDC) database on November 4, 2022, at 10:00 UTC.
The PDS6 dataset encompasses data exclusively from Enroll-HD participants, collected from several sources. These sources are the Enroll-HD study, the REGISTRY study, and clinical data collected in adhoc visits outside of the aforementioned studies.
Enroll-HD is an observational cohort study and global clinical research platform designed to facilitate Huntington’s disease (HD) clinical research. It includes participants from North America, Europe, Australasia, and Latin America. The study started in 2012 and is still active and actively recruiting.
REGISTRY is an observational cohort study of HD conducted in Europe. The study started in 2004 and concluded in 2015. As Enroll-HD began, REGISTRY sites and participants began to transition into Enroll-HD. Enroll-HD dataset releases include individuals who initially participated in REGISTRY then consequently enrolled in Enroll-HD and consented to the migration of their REGISTRY data into the Enroll-HD dataset. Registry data are available for a subset of Enroll-HD participants.
Clinical data from additional sources (Ad Hoc data) are available for a subset of Enroll-HD participants. These data were collected at routine clinical visits outside of the Enroll-HD and REGISTRY studies, and comprise HD assessment data (e.g., UHDRS Motor). The date of collection of these data typically pre-date a participant’s enrolment into REGISTRY or Enroll-HD.
Study specific protocols, annotated eCRFs, and data collection guidelines are housed here.
To be included in the PDS5 release, participant’sdata had to meet several requirements. Figure 1.1 illustrates the number of participants whose data met each of the predefined inclusion requirement and illustrates how the final sample size of PDS5 was determined.
Due to data exclusion requirements, not all participants enrolled in Enroll-HD at the time of PDS6 data cut are included in PDS6. Similarly, not all participants included in PDS5 are included in PDS6. Data from 200 participants who were included in PDS5 were not included in the current PDS release. Enroll-HD is an active, longitudinal study. A participant eligible for inclusion for one release may be ineligible the next (e.g., participant data quarantined). Data for PDS5 participants not included in PDS6 may be available through specified dataset (SPS) request.
PDS5 contains data on 21,116 Enroll-HD participants. Sample size by PDS release is presented in Figure 1.2 .
PDS6 contains data from 95,041 visits (baseline and follow-up visits only; all sources). Of these, 78,730 were Enroll-HD visits. The remainder are from Registry (N = 15,292) and ‘Ad Hoc’ sources (N = 1,018). A breakdown of visits by data source is provided in Table 1.1. Number of Enroll-HD visits only by PDS release are illustrated in Figure 1.3.
Considering baseline and follow-up visits from Enroll-HD only, total number of visits per participant in PDS5 ranges from 1 to 11. In @ref(fig:lollipop_visits) , we illustrate participant counts by maximum number of Enroll-HD visits. Each participant is represented once, included in the bar indicative of their maximum number of visits. In @ref(fig:lollipop_visits_cumulative), we illustrate maximum participant counts for a specific number of visits. This plot is cumulative, the goal being to illustrate largest available sample size for a specific number of visits. For example, the participant with 9 visits is represented in visit bars 1 through 9, the participants with 8 visits are represented in visit bars 1 through 8, and so on.
Considering baseline and follow-up visits from all data sources (Enroll-HD, REGISTRY, Ad Hoc visits), total number of visits per participant ranges from 1 to >20. Maximum participant counts by visit number are presented in @ref(fig:lollipop_visits_cumulative_stdy).
The PDS6 sample is characterized below with respect to participant category, sociodemographic variables, and clinical characteristics (Figures 7 to 19).